NCT04233060 - A Study of CS3005 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

February 17, 2021

Conditions

Advanced Solid Tumor

Interventions

DRUG

CS3005

CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)

Trial Locations (1)

2031

Scientia Clinical Research Ltd, Sydney